An EU drug authorization database is the single most important research tool for pharmaceutical professionals who need to know which medicines are authorized in which countries. Whether you are sourcing reference products for a generic application, identifying market gaps for business development, or tracing active ingredients across international brand names, the ability to search one consolidated european medicine database eliminates days of fragmented research across dozens of national registries.

An EU drug authorization database is a consolidated data platform that aggregates marketing authorization records from multiple European and international countries into a single searchable interface. It answers a deceptively simple question: which medicines are authorized where, by whom, and with what active ingredients?

This matters because the European pharmaceutical market is not a single market. A product authorized in France may carry a different brand name in Poland, be manufactured by a different marketing authorization holder (MAH) in Turkey, and be entirely unavailable in Germany. Without a consolidated database, answering cross-border questions requires navigating individual national agencies, each with its own language, search interface, and data format.

For professionals in regulatory affairs, market access, import/export, and business development, an EU drug authorization database serves four core functions:

• Market research — Identify which products exist in which countries and who holds the authorization
• Import sourcing — Locate authorized products abroad when domestic supply is unavailable or discontinued
• Regulatory referencing — Find reference products and well-established use evidence across jurisdictions
• Competitive landscape analysis — Map competitors by country, active ingredient, and therapeutic area

Data Scope: What’s Inside

The pharmazie.com EU database contains 120,000+ international pharmaceutical products across more than 50 countries. This includes EU member states, EEA countries, Switzerland, the United Kingdom, Turkey, and selected markets in the Middle East, Asia, and the Americas.

Each product record includes structured, searchable fields:

The Active Pharmaceutical Ingredient Database

The active pharmaceutical ingredient database within pharmazie.com is a comprehensive registry of every active substance used in authorized medicines worldwide. Each ingredient entry includes all internationally recognized synonyms: INN (International Nonproprietary Name), BAN (British Approved Name), USAN (United States Adopted Name), and WHO designations.

Beyond nomenclature, every active ingredient is linked to its chemical group, pharmacological classification, and — critically — every brand name product containing that ingredient, organized by country. This makes it possible to start from a single substance and immediately see the full global landscape of products built around it.

How Cross-Linking Creates Intelligence

Raw data becomes intelligence when records are connected. The pharmazie.com platform cross-links its 25+ integrated databases so that every search opens multiple investigative paths. This is the principle behind the Iceberg Search: one query surfaces results across all connected datasets simultaneously.

A typical navigation pattern works like this:

1. Search an active ingredient (e.g., Isradipine)
2. View all brand name products containing that ingredient across all 50+ countries
3. Click any brand name to see full MAH details, dosage forms, and strengths
4. Navigate to the ATC hierarchy (C08CA03 — Isradipine, within C08CA — Dihydropyridine derivatives) to find therapeutic alternatives
5. Identify market gaps — countries where products exist vs. countries where they do not

Everything loops. The active pharmaceutical ingredient database connects to international product records. International products connect to German drug pricing data. German pricing connects to shortage data. Shortage data connects back to the EU database for sourcing alternatives. This interconnected architecture means that a single search query can answer questions that would otherwise require consulting five or six separate systems.

Example: Isradipine — From Gap to Opportunity

Consider the calcium channel blocker Isradipine. A search in pharmazie.com reveals that no product containing Isradipine is currently marketed in Germany. Navigating to the EU database shows authorized products in Belgium (DynaCirc), France (Icaz), Italy (Lomir), Poland (Lomir), and Turkey (Lomir). Each record includes the local MAH, available strengths, and dosage forms.

For a business development professional, this represents a potential market entry opportunity. For an import specialist, it identifies sourcing countries for Article 73.3 imports. For a regulatory affairs manager, it provides reference product candidates for a generic application. One search, three actionable outputs.

Use Cases for Different Teams

Regulatory Affairs

Regulatory professionals rely on international authorization data at nearly every stage of the product lifecycle. Key applications include:

• Reference product identification — Locate the originator product across EU markets for generic or biosimilar applications, including markets where the reference product may still be authorized even if withdrawn domestically
• Well-established use evidence — Document that an active substance has been in medicinal use for at least 10 years within the EU, using authorization records from multiple member states
• Discontinued product research — Cross-reference the pharmazie.com discontinued products archive to determine whether a withdrawal was safety-related or commercial, a distinction critical for Article 10 applications
• Variation benchmarking — Compare how the same product is authorized across jurisdictions (strengths, indications, formulations) to support variation applications

Business Development

The EU drug authorization database is a market intelligence tool when used strategically. Business development teams use it to:

• Identify market gaps — Products authorized in multiple EU countries but absent from Germany (or any target market) represent potential licensing or launch opportunities
• Find licensing partners — The MAH in a source country is often the first point of contact for in-licensing discussions; the database provides this information directly
• Map competitive landscapes — Filter by ATC code and country to see exactly which competitors operate in each market, with which products, and at which strengths
• Monitor market entry — Track new authorizations in adjacent markets as early indicators of potential competitive moves

Import/Export and Parallel Trade

For pharmaceutical wholesalers and importers, the database serves as a sourcing tool:

• Article 73.3 import sourcing — When a product is unavailable in Germany due to a supply shortage, identify authorized equivalents in other EU/EEA countries that can be imported under the emergency import provision
• Price comparison across countries — Cross-reference international authorization data with pricing databases to identify parallel import opportunities where price differentials justify cross-border trade
• Parallel import documentation — Gather the authorization details (MAH, product name, country) required for parallel import license applications

Comparing EU Drug Databases

Not all EU drug databases cover the same ground. The differences between available options are significant, and choosing the wrong one can leave critical blind spots in your research.

The European Medicines Agency medicines database is an authoritative source, but it only covers centrally authorized products — those that received a single EU-wide marketing authorization through the EMA. The vast majority of medicines in Europe are authorized nationally, through individual member state procedures (national, mutual recognition, or decentralized). These products do not appear in the EMA database.

National databases such as the French ANSM or the UK MHRA cover their respective markets comprehensively but present two problems: language barriers and the absence of cross-linking. To research the same active ingredient across ten countries, you would need to search ten separate databases in up to ten different languages.

The pharmazie.com EU database consolidates nationally and centrally authorized products from 50+ countries into a single interface, cross-linked with German drug pricing, shortage data, and the active pharmaceutical ingredient database. This consolidation is what transforms isolated records into actionable intelligence.

Frequently Asked Questions

Does the EU database include nationally authorized products?

Yes. Unlike the EMA medicines database, which only lists centrally authorized products (those with an EU-wide marketing authorization), the pharmazie.com EU database includes both centrally and nationally authorized products from more than 50 countries. This covers products authorized through national procedures, mutual recognition procedures (MRP), and decentralized procedures (DCP) — the vast majority of medicines available in European markets.

How current is the international product data?

The international product database is updated on a regular schedule, with update frequency varying by country and data source. Core EU markets receive the most frequent updates. Because national registries publish updates at different intervals, pharmazie.com aggregates data as it becomes available from each source. For time-critical decisions such as import sourcing during shortages, the database is complemented by daily-updated German shortage data that flags when international alternatives become relevant.

Can I filter by country of authorization?

Yes. The database supports filtering by country of authorization, allowing you to narrow results to specific markets. You can also search across all countries simultaneously and then filter the results, which is useful when you need to determine the full geographic footprint of a particular active ingredient or brand name. Combined with ATC code filtering and MAH search, this enables precise competitive landscape analysis for any target market.

Is the Swiss drug database included?

Yes. Switzerland is included in the pharmazie.com international product database despite not being an EU or EEA member state. Swiss authorization data from Swissmedic is integrated alongside EU member state data, making it possible to include Switzerland in cross-border product research, pricing comparisons, and sourcing analysis. This is particularly relevant for parallel trade and import/export professionals operating in the DACH region.

How does the EU database connect to shortage data?

The EU drug authorization database is directly cross-linked with the pharmazie.com German drug shortage database. When a product is flagged as unavailable in Germany, the system can identify the same active ingredient in products authorized in other countries — providing a list of potential import alternatives. This connection between shortage monitoring and international authorization data is essential for pharmacies and wholesalers managing supply disruptions under Article 73.3 import provisions. Explore all available datasets on the databases overview page.